| Title |
Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models
|
|---|---|
| Published in |
Archives of Toxicology, December 2017
|
| DOI | 10.1007/s00204-017-2146-z |
| Pubmed ID | |
| Authors |
José Miguel P. Ferreira de Oliveira, Ana Rita Pacheco, Laura Coutinho, Helena Oliveira, Sónia Pinho, Luis Almeida, Eduarda Fernandes, Conceição Santos |
| Abstract |
Osteosarcoma chemotherapy is often limited by chemoresistance, resulting in poor prognosis. Combined chemotherapy could, therefore, be used to prevent resistance to chemotherapeutics. Here, the effects of fisetin on osteosarcoma cells were investigated, as well as cytostatic potential in combination with the anti-cancer drug etoposide. For this, different osteosarcoma cell lines were treated with fisetin, with etoposide and with respective combinations. Fisetin was associated with decrease in colony formation in Saos-2 and in U2OS cells but not in MG-63 cells. Notwithstanding, upon evaluation of cellular growth by crystal violet assay, MG-63 and Saos-2 cells showed decreased cell proliferation at 40 and 20 µM fisetin, respectively. Depending on the relative concentrations, fisetin:etoposide combinations showed negative-to-positive interactions on the inhibition of cell proliferation. In addition, fisetin treatment up to 50 µM for 48 h resulted in G2-phase cell cycle arrest. Regardless of the combination, fisetin:etoposide increased % cells in G2-phase and decreased % cells in G1-phase. In addition, mixtures with more positive combined effects induced increased % cells in S-phase. Compared to etoposide treatment, these combinations resulted in decreased levels of cyclins B1 and E1, pointing to the role of these regulators in fisetin-induced cell cycle arrest. In conclusion, these results show that the combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent, which has important implications for osteosarcoma treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 29% |
| Researcher | 3 | 11% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Bachelor | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Other | 5 | 18% |
| Unknown | 5 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 7 | 25% |
| Agricultural and Biological Sciences | 4 | 14% |
| Medicine and Dentistry | 2 | 7% |
| Unspecified | 1 | 4% |
| Psychology | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 10 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 May 2019.
All research outputs
#20,459,801
of 23,016,919 outputs
Outputs from Archives of Toxicology
#2,381
of 2,653 outputs
Outputs of similar age
#376,324
of 440,672 outputs
Outputs of similar age from Archives of Toxicology
#26
of 31 outputs
Altmetric has tracked 23,016,919 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,653 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 440,672 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.